close

Enter

Log in using OpenID

Primary Biliary Cholangitis Treatment Market

embed
Primary Biliary Cholangitis Treatment Market Size, Share, Growth, Outlook, and Opportunity
Analysis, 2018-2026
Primary Biliary Cholangitis (PBC) is a rare disease characterized by chronic progressive liver
disorder. It majorly affects women and usually occurs in middle age ranging between 30 to 60 years.
It is also called as biliary cirrhosis. PBC tends to affect the small bile duct present in the liver. Primary
biliary cholangitis is divided into four stages including stage 1 with no significant scarring to stage 4
known as cirrhosis. PBC is triggered by the combination of factors such as autoimmune, genetic, and
environmental factors.
Request Sample Copy of Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/2555
Increasing number of Food and Drug Administration (FDA) approvals for the drugs to treat PBC is
contributing to the market growth. For instance, in May 2016, the U.S. Food and Drug Administration
(FDA) approved Ocaliva (obeticholic acid) in combination with ursodeoxycholic acid (UDCA) for the
treatment of Primary Biliary Cholangitis (PBC) in adults with an inadequate response to UDCA.
Furthermore, in 2016, Ocaliva was assigned fast track designation and orphan drug designation by
the U.S. FDA.
Increasing number of pipeline studies is expected to drive the primary biliary
cholangitis treatment market growth
Increasing pipeline studies to develop prominent treatments for rare diseases such as primary
biliary cholangitis are expected to boost the primary biliary cholangitis treatment market size.
For instance, in October 2018, CymaBay Therapeutics, Inc., initiated placebo-controlled and
randomized phase 3 clinical trial for seladelpar 5-10mg. The aim of the study was to evaluate
safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC) and to
determine inadequate response or intolerance to ursodeoxycholic acid (UDCA). The study is
estimated to complete in December 2021.
Report includes chapters which deeply display the following deliverable about industry :
• Primary Biliary Cholangitis Treatment Market Research Objective and Assumption
• Primary Biliary Cholangitis Treatment Market Purview - Report Description, Executive Summary,
and Coherent Opportunity Map (COM)
• Primary Biliary Cholangitis Treatment Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Primary Biliary Cholangitis Treatment Market, By Regions
• Primary Biliary Cholangitis Treatment Market Competition by Manufacturers including Production,
Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Primary Biliary Cholangitis Treatment Market Manufacturers Profiles/Analysis including Company
Basic Information, Manufacturing Base and Its Competitors.
• Primary Biliary Cholangitis Treatment Market Manufacturing Cost Analysis including Key Raw
Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning
and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Primary Biliary Cholangitis Treatment Market Forecast including Production, Consumption, Import
and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Primary Biliary Cholangitis Treatment Market - Competitive Landscape
Key players operating in the primary biliary cholangitis treatment market include
Novartis
AG,
Bristol-Myers
Squibb,
NGM
Biopharmaceuticals,
Lumena
Pharmaceuticals, Inc., TARGET PharmaSolutions, Inc., Intercept Pharmaceuticals, Inc.,
Teva Pharmaceutical Industries Ltd, Retrophin, Inc., Calliditas Therapeutics AB., and
GlaxoSmithKline (GSK) pharmaceutical.
Inquire Here Before Purchase: https://www.coherentmarketinsights.com/insight/talk-toanalyst/2555
Detailed Segmentation:
• Global Primary Biliary Cholangitis Treatment Market, By Treatment Type
• Ursodeoxycholic acid (UDCA)
• Obeticholic acid (Ocaliva)
• Global Primary Biliary Cholangitis Treatment Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Primary Biliary Cholangitis Treatment Market, By Region:
• North America
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
20   documents Email
Document
Category
Health and Medicine
Views
1
File Size
154 KB
Tags
primary
1/--pages
Report inappropriate content